CATL and Ant Group’s planned listings could break recent HK IPO records; The lowering of U.S. drug prices will impact Chinese drugmakers; and U.S. House passes sanctions bill targeting trade secret theft by China.
Chinese exporters ship goods through third countries to conceal true origin; China’s stringent cross-border data transfer rules force European pause in funding of scientific research; and Draft revisions of arbitration law aim to increase oversight and international cooperation on arbitration cases
Beijing IP Court issues first ruling on protecting AI model parameters; Chinese pharma companies are using “NewCo” strategy to expand overseas; and China reduces entry restrictions for select industries.
China eases cross-border data transfer restrictions for financial institutions; Trade war prompts plan to open up service sector; and new law firm anti-money laundering regulations to align with international standards
The Cyberspace Administration clarifies its approach to the export of personal and important information out of China; UK weighs whether to include China in foreign influence disclosure rules; and Burberry wins online trademark infringement suit.
China to block Chinese firms from investing in the U.S. amid tariff war; Shenzhen launches incentives for foreign-owned hospitals following national legislation; and U.S. companies plan continuous engagement with China
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
